Body Good Studio
GLP1 EDUCATION

What Is Ozempic? How It Works for Weight Loss

Dr. Linda Moleon, MDβ€’May 12, 2026




What Ozempic Actually Does β€” And Why It's Changing Weight Loss Medicine

If you've heard the word ozempic more times this year than you can count, you're not alone. It's in headlines, social feeds, and conversations at the doctor's office. But behind the buzz is a real medication with a real mechanism β€” and understanding how it works can help you decide whether it belongs in your health plan.

Ozempic (semaglutide) was originally FDA-approved in 2017 for type 2 diabetes management. Since then, clinical research has revealed something clinicians had begun to suspect: it also produces meaningful, sustained weight loss. That insight led directly to Wegovy β€” the higher-dose semaglutide formulation FDA-approved specifically for chronic weight management in 2021. Today, both medications are reshaping how clinicians approach metabolic health, and the evidence base is substantial.

Here's what's actually happening in your body when you take it β€” and why it works differently than anything that came before. For more context on how GLP-1 medications compare and overlap, explore the GLP-1 education articles on our blog.

How Ozempic Works: The GLP-1 Mechanism

Ozempic belongs to a class of medications called GLP-1 receptor agonists (glucagon-like peptide-1). GLP-1 is a hormone your gut naturally produces after you eat. It signals the pancreas to release insulin, tells the liver to slow glucose production, and β€” critically β€” sends satiety signals to the brain.

When you inject semaglutide once weekly, you're amplifying that hormonal signal continuously. The result is a multi-pronged metabolic effect:

  • β€’ Slowed gastric emptying: Food moves through your stomach more slowly, keeping you fuller longer after meals.

  • β€’ Reduced appetite signaling: The hypothalamus receives stronger satiety messages, reducing hunger between meals.

  • β€’ Improved insulin sensitivity: Blood sugar is regulated more efficiently, reducing the energy crashes that trigger cravings.

  • β€’ Reduced food reward response: Emerging research suggests GLP-1 receptors in the brain's reward centers may reduce the psychological pull of high-calorie foods.
  • This isn't about willpower. It's pharmacology working with your biology β€” and that distinction matters for how people experience the medication.

    What the Clinical Evidence Shows

    The STEP clinical trial program β€” one of the largest weight loss drug studies ever conducted β€” evaluated semaglutide 2.4mg (Wegovy) in adults with obesity or overweight plus at least one weight-related health condition. Results published in the New England Journal of Medicine showed an average body weight reduction of 14.9% over 68 weeks in participants who combined the medication with lifestyle counseling. That's roughly three times the weight loss typically achieved with lifestyle changes alone.

    STEP 1 enrolled over 1,900 participants. STEP 2 focused on adults with type 2 diabetes, where weight loss was somewhat attenuated but still clinically meaningful. STEP 3 showed that combining semaglutide with intensive behavioral support produced greater results. STEP 4 demonstrated that participants who discontinued the medication regained most of the weight within a year β€” underscoring that this is ongoing treatment, not a one-time intervention.

    For context, the tirzepatide trials (the SURMOUNT program) achieved even higher average weight loss β€” up to 20.9% body weight reduction β€” because tirzepatide acts on both GLP-1 and GIP receptors simultaneously. Both medications represent a genuine clinical advance. The science here is not ambiguous.

    Ozempic vs. Wegovy: The Dose Distinction

    This causes more confusion than almost anything else in the GLP-1 conversation. Ozempic and Wegovy contain the same molecule β€” semaglutide β€” but at different approved doses and for different indications:

    | | Ozempic | Wegovy |
    |---|---|---|
    | Active ingredient | Semaglutide | Semaglutide |
    | Approved for | Type 2 diabetes | Chronic weight management |
    | Max dose | 2mg weekly | 2.4mg weekly |
    | Insurance criteria | Diabetes diagnosis required | BMI criteria required |

    When people say they are on ozempic for weight loss, they may actually be on Wegovy β€” or receiving semaglutide through a licensed prescriber who has determined it's clinically appropriate for their situation. The distinction matters most for insurance coverage and dosing protocols.

    If you're curious whether you qualify for a GLP-1 program, our free 60-second eligibility quiz can give you a starting point before you ever speak to a clinician.

    Who Is a Candidate?

    FDA labeling for Wegovy specifies adults with:

  • β€’ BMI of 30 or higher (classified as obesity), or

  • β€’ BMI of 27 or higher (overweight) plus at least one weight-related health condition such as hypertension, type 2 diabetes, or dyslipidemia
  • In practice, a licensed clinician reviews your full health history β€” not just a single number. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use semaglutide. A history of pancreatitis warrants careful clinical evaluation. Pregnancy is a contraindication.

    The intake review isn't bureaucratic checkbox-ticking β€” it's how your prescribing clinician ensures the medication is appropriate and safe for your specific situation.

    At Body Good Studio, every patient receives a clinical intake review by a licensed provider before any prescription is issued. You can check your insurance probability to see what your plan may cover before your consultation.

    What to Expect: The Titration Timeline

    Semaglutide is always started at a low dose and increased gradually over weeks to months. This titration schedule exists for an important reason: it significantly reduces gastrointestinal side effects like nausea, vomiting, and diarrhea β€” which are the most common reasons people discontinue early.

    Typical titration schedule (Wegovy protocol):

  • β€’ Weeks 1–4: 0.25mg weekly

  • β€’ Weeks 5–8: 0.5mg weekly

  • β€’ Weeks 9–12: 1.0mg weekly

  • β€’ Weeks 13–16: 1.7mg weekly

  • β€’ Week 17 onward: 2.4mg weekly (maintenance dose)
  • Many people experience mild nausea during dose increases, particularly in the first few weeks. This typically improves as the body adjusts to higher semaglutide levels. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated all help manage this phase.

    Some practical guidance you can apply this week: if you're starting or titrating, front-load calories earlier in the day when nausea tends to be lower, prioritize protein at every meal to preserve lean muscle mass, and don't skip meals assuming it will accelerate results β€” it typically worsens side effects without adding benefit.

    Nutrition and Movement: Why They Still Matter

    Ozempic and Wegovy are not meal replacements. They're tools that make behavioral changes more achievable by reducing the biological pressure of hunger and food preoccupation. The clinical trials that demonstrated weight loss paired medication with lifestyle counseling for a reason β€” the combination outperforms either approach alone.

    The nutrition approach that works best alongside GLP-1 medications:

  • β€’ Higher protein intake (targeting 0.7–1g per pound of lean body mass) to minimize muscle loss during weight reduction

  • β€’ Whole foods emphasis β€” ultra-processed foods tend to worsen GI side effects and reduce the quality of weight lost

  • β€’ Consistent meal timing β€” irregular eating patterns can amplify nausea during titration

  • β€’ Adequate hydration β€” important because GI side effects increase fluid loss
  • Movement does not need to be intense to be effective. Resistance training β€” even bodyweight exercises β€” is particularly valuable during weight loss because it helps preserve muscle, which supports long-term metabolic health. Walking 7,000–10,000 steps daily has robust evidence for cardiovascular and metabolic benefit with minimal barrier to entry.

    Our medical weight loss programs include nutritional guidance integrated into the clinical protocol β€” not as an optional add-on, but as part of how the program is designed to work.

    Telehealth and Access: What the Path Looks Like

    One of the biggest barriers to GLP-1 treatment has historically been access β€” getting an appointment, navigating insurance, and affording the medication. Telehealth has meaningfully changed that calculus.

    Through a licensed telehealth provider, the typical path looks like this:
    1. Complete a clinical health intake (online, roughly 10–15 minutes)
    2. Review with a licensed clinician, often same-day or next-day
    3. Prescription issued if clinically appropriate
    4. Medication shipped discreetly to your address

    Insurance coverage for Wegovy and compounded semaglutide varies significantly. Some plans cover GLP-1s for diabetes but not weight management. Some cover both. Others cover neither. Knowing before you start saves time and sets realistic expectations.

    Transparent pricing matters here. Programs that require you to call for a quote, or that bury medication costs in membership tiers, make it harder to plan your care. Medical weight loss should be about outcomes, not a sales experience.

    Frequently Asked Questions

    Is Ozempic the same as Wegovy?


    They contain the same active ingredient β€” semaglutide β€” but Ozempic is FDA-approved for type 2 diabetes and Wegovy is approved for chronic weight management at a higher dose (2.4mg versus 2mg). Insurance coverage criteria differ between the two, so the distinction matters practically.

    How long does it take to see results on semaglutide?


    Most people notice appetite reduction within the first one to two weeks. Meaningful weight loss typically becomes visible between weeks 8–12, with more substantial changes occurring across the full treatment period. The STEP trials tracked outcomes over 68 weeks for a reason.

    Can you stop taking Ozempic once you reach your goal weight?


    The STEP 4 trial showed that participants who discontinued semaglutide regained most of the weight within the following year. Like treatment for other chronic conditions, ongoing use is typically required to maintain outcomes. Your clinician can help you evaluate options based on your situation.

    What are the most common side effects?


    Nausea, vomiting, diarrhea, and constipation are most common, particularly during dose increases. These are generally mild to moderate and improve with time. Rare but serious adverse events include pancreatitis and gallbladder disease β€” which is precisely why clinician supervision matters throughout treatment.

    Is Ozempic covered by insurance?


    Coverage varies significantly by plan. Ozempic is frequently covered when prescribed for type 2 diabetes. Wegovy coverage for weight management is more variable and often requires documentation of qualifying conditions. Body Good Studio's insurance probability checker can give you a quick estimate before you commit time to an appointment.

    Ready to start your weight loss journey?

    Body Good Studio's clinician-prescribed programs make medical weight loss accessible, affordable, and personalized. Take our free 60-second quiz to see if you qualify β€” most members get a treatment plan in under 24 hours.

    Ready to get started?

    Take our quiz to find the perfect program for you.

    Take the Quiz